Comprehensive Monoclonal Antibody Generation
By screening and expressing the VH and VL domains of B cell libraries, and using a biological display system to screen for high-affinity antibodies, the problems of low efficiency and high cost in monoclonal antibody production in existing technologies have been solved, achieving efficient and economical antibody diversity and screening.
Patent Information
- Application Number
- CN201610287362.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2011-01-04
- Filing Date
- 2011-12-28
- Publication Date
- 2016-09-07
- Estimated Expiration
- 2031-12-28
AI Technical Summary
Existing hybridoma methods are inefficient and genetically unstable in producing monoclonal antibodies, making it difficult to effectively analyze and utilize the vast antibody diversity of the mammalian immune system. Furthermore, existing methods are expensive and time-consuming.
By screening B cell libraries, expanding and expressing immunoglobulin libraries with VH and VL domains, screening and expressing antibodies using a biological display system, binding to target antigens to identify high-affinity recombinant antibodies, and employing high-throughput screening and deep sequencing technologies to improve efficiency.
This technology enables the efficient and economical production and identification of high-affinity monoclonal antibodies, significantly improving antibody diversity and screening efficiency while reducing operating costs and time.